Skip to content
Banking, Finance Investment

Remittance firm LemFi eyes global expansion with Visa Cross-Border Solutions deal

Visa < 1 mins read

 

 

  • Visa Cross-Border Solutions and LemFi, the UK-headquartered international payments company, have signed a global expansion deal
  • The deal will enable LemFi to extend its reach into several new markets around the world

 

Visa Cross-Border Solutions, a Visa (NYSE: V) division specialising in cross-border money movement, and LemFi, a leading international payments company, have signed a deal that significantly expands their existing partnership globally.  

 

The deal will enable LemFi to extend its reach into new markets around the globe including China, India & Pakistan, with Visa Cross-Border Solutions becoming its primary partner in facilitating cross-border transactions. The partnership will also allow Visa to provide debit and pre-paid debit cards to over 250,000 users in the UK and EMEA regions. 

 

Ridwan Olalere, CEO and Co-founder of LemFi, said: “The combination of our expertise and our technology platform puts us in a very strong position to expand internationally in the coming months and years. Visa’s speed-to-market, transparency and scalability will be instrumental as we extend our services worldwide.” 

 

The cross-border money movement specialist will also continue as the preferred provider of e-payments and foreign exchange services for LemFi, supporting the remittance of funds for hundreds of thousands of UK-based citizens from various African countries. 

 

Piers Marais, Head of Product at Visa Cross-Border Solutions, said: “LemFi is doing incredible work with nationals from countries in Africa – and we know the enormous impact that remittances have in that part of the world.

 

“The next step for them to grow as a business is for them to take that expertise and apply it globally. We’re so excited to be on that journey with them”.

 

 

 

 

 

More from this category

  • Finance Investment
  • 13/01/2026
  • 13:40
Moomoo

Focused on AI, Australian investors expect 2026 to deliver

SYDNEY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Australian investors have started the new year with an overwhelming appetite for artificial intelligence and expectations of solid returns from their increasingly global portfolios, a comprehensive new survey by stock broking firm Moomoo Australia and New Zealand reveals.The detailed survey of more than 600 Australian investors' expectations and intentions for the year complements the release of moomoo's 2026 Market Outlook today, where our local experts and global research team analyse key trends in financial markets for the year ahead.And this year, investors are committing to high-growth sectors, including AI – showing a willingness…

  • Finance Investment, Oil Mining Resources
  • 13/01/2026
  • 10:22
Jane Morgan Management

Patriot Resources reports significant silver and gold results validating Kitumba polymetallic target in Zambia

Perth, Australia – 13 January 2026: Patriot Resources Limited (ASX: PAT) has reported significant silver and gold assay results from its Phase 1 trenching program at Target B1 within the Company’s 80%-owned Kitumba 27715 Project in Zambia, further validating the prospect as a near-surface polymetallic system. The latest results add silver and gold credits to previously announced strong copper, zinc and lead geochemistry, reinforcing the scale and potential economic significance of the mineralised system. The Company said the combination of metals highlights a unique polymetallic signature and strengthens confidence in Target B1 as a priority focus for ongoing exploration. Notable…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.